Investor Overview Announcements Date Title 2021/03/17 OBI filed the application to EMA for Phase III human clinical study of the active cancer immunotherapy OBI-822, Adagloxad Simolenin, in Spain, German, and Poland 2021/03/12 The Board of Directors resolved to hold 2021 Annual General Meeting Read More Annual Report 2019Annual Report (PDF) 2018Annual Report (PDF) See More Financial Report 2020Financial Report Q1 2019Financial Report Q1 See More Stock Quote See More Event Calendar See More Monthly Revenues See More Corporate GovernanceRead More StakeholderRead More Company Profile Read More
